Biotech/Biopharma Analysts discuss SURMOUNT, a clinical trial for participants with Obstructive Sleep Apnea (OSA) on an Analyst/Industry conference call to be held on February 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- ‘Load Up,’ Says Wells Fargo About Eli Lilly Stock
- Eli Lilly price target raised to $700 from $650 at Wells Fargo
- Eli Lilly unit says participant in Phase 1/2 study had hearing restored
- Zealand Pharma believes it can compete in weight-loss drug market, FT says
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits